Showing results (171-180 of 723) with videos related to

Sort By:
Pageof 73
Endocrinology|December 26, 2001
Thiazolidinediones influence plasma steroids of male obese Zucker ratsClemens Fürnsinn, Peter Nowotny, Barbara Brunmair, et al.
Diabetologia|April 28, 2021
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysisSabrina Schlesinger, Manuela Neuenschwander, Alexander Lang, et al.
The Journal of Clinical Endocrinology and Metabolism|May 3, 2007
Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunctionFriedrich Mittermayer, Georg Schaller, Johannes Pleiner, et al.
Frontiers in Physiology|March 2, 2023
Positive allosteric GABAA receptor modulation counteracts lipotoxicity-induced gene expression changes in hepatocytes in vitroElisabeth Rohbeck, Corinna Niersmann, Karl Köhrer, et al.
Diabetes|June 28, 2003
Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patientsChristian Anderwald, Georg Brabant, Elisabeth Bernroider, et al.
Diabetologia|May 3, 2015
Overexpression of cutaneous mitochondrial superoxide dismutase in recent-onset type 2 diabetesDan Ziegler, Alexander Strom, Jutta Brüggemann, et al.
The Journal of Clinical Endocrinology and Metabolism|April 6, 2006
The role of endocrine counterregulation for estimating insulin sensitivity from intravenous glucose tolerance testsAttila Brehm, Karl Thomaseth, Elisabeth Bernroider, et al.
Diabetes Care|February 5, 2013
Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER studyBen Schöttker, Christian Herder, Dietrich Rothenbacher, et al.
Nature Reviews. Drug Discovery|June 6, 2022
Thinking outside the box: non-canonical targets in multiple sclerosisLaura Bierhansl, Hans-Peter Hartung, Orhan Aktas, et al.
Acta Diabetologica|July 25, 2022
Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient dataOliver Kuss, Cihan Akbulut, Sabrina Schlesinger, et al.
Pageof 73